Vertex Pharmaceuticals reported revenues of US$2.6b, in line with expectations, but also reported losses of US$13.92 per share, slightly higher than expected. Analysts forecast a 4.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
